title: [Dual therapy as an alternative treatment in HIV pretreated patients: experience in a tertiary hospital].
abstract: OBJECTIVE
  Dual therapy regimen might be an effective alternative to prevent the occurrence of side effects and comorbidities associated with prolonged treatment with antiretroviral (ARV) and a way of simplification of antiretroviral therapy (ART) to improve adherence in certain patients. It also represents a potential treatment option for patients who have failed previous TAR.
  
  
  METHODS
  The aim of the study is to describe the effectiveness, adherence and costs of dual therapy regimen used in pretreated HIV patients in tertiary hospital.
  
  
  RESULTS
  Thirty-eight patients were studied (eight were excluded). Reasons for simplification to dual therapy were previous treatment toxicity (40%), simplification (36.67%) and virological rescue (20%). The dual therapy regimens most used were: IP/r + INSTIs (26.67%), IP/r + NRTIs (23.33%), IP/r + NNR-TIs (23.33%), IP/r+ CCR5 (16.66%) e INSTIs + NNRTIs (10%). ARV more used were darunavir/ritonavir (DRV/r) + raltegravir (23.33 %); DRV/r + lamivudine (20%) y DRV/r + etravirine (16.67 %). Adherence was 86.79% before switching to dual therapy and 96.27% after switching. The cost savings of switching to dual therapy of these patients was € 3,635.16.
  
  
  CONCLUSIONS
  Dual therapy with IP/r might be an effective alternative to selected treatment experienced patients compared with conventional therapy.
authors.forename: Lucia
authors.initials: L
authors.lastname: Yunquera-Romero
authors.affiliation: Rocío Asensi Diez, Servicio de Farmacia. Hospital Regional Universitario de Málaga. Dirección: Avenida de Carlos Haya s/n. CP.29010. Málaga. Spain. rocio.asensi.sspa@juntadeandalucia.es.
authors.forename: Rocío
authors.initials: R
authors.lastname: Asensi-Díez
authors.forename: Macarena
authors.initials: M
authors.lastname: Gajardo-Álvarez
authors.forename: Isabel
authors.initials: I
authors.lastname: Muñoz-Castillo
mesh_terms: D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000191:economics / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects / Q000191:economics; D004359:Drug Therapy, Combination; D005260:Female; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy* / Q000191:economics; D017320:HIV Protease Inhibitors / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D062606:Tertiary Care Centers
chemical_list: D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors